Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Cormedix ( (CRMD) ) is now available.
On June 23, 2025, CorMedix Inc. announced that its Large Dialysis Organization customer has started ordering and will begin implementing DefenCath in the second half of 2025, targeting at least 50% more patients than previously anticipated. This expanded utilization has led to an amended agreement with the customer and is expected to contribute modestly to revenue in June, with further growth projected for the latter half of 2025. Consequently, CorMedix has increased its second-quarter net sales guidance to a range of $35 million to $40 million, reflecting positive business developments and the broader access to DefenCath for patients at risk of catheter-related bloodstream infections.
The most recent analyst rating on (CRMD) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Neutral.
Cormedix’s overall stock score is influenced by a challenging financial position, marked by ongoing losses and negative cash flows. Despite technical indicators showing potential downward pressure, the recent earnings call provides a positive outlook with record-breaking revenue and strategic growth initiatives. However, valuation concerns and operational challenges remain significant obstacles.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The company is primarily focused on its lead product, DefenCath, which is used to prevent catheter-related bloodstream infections.
Average Trading Volume: 2,068,099
Technical Sentiment Signal: Buy
Current Market Cap: $923.1M
See more data about CRMD stock on TipRanks’ Stock Analysis page.